After failing androgen deprivation therapy (ADT), patients develop metastatic castration-resistant prostate cancer (mCRPC), which is associated with a poor prognosis and a 5-year survival rate of 15% [4,5].The transmembrane protein (84 kDa) prostate-specific membrane antigen (PSMA) shows a distinct overexpression on PC cells, which increases with a higher Gleason score and metastatic disease [6,7,8,9]. This evidence concerns the gene FOLH1 and metastatic neoplasm.